TY - JOUR
T1 - Therapeutic drugs for SARS-CoV-2 treatment
T2 - Current state and perspective
AU - Bolarin, Joshua Adedeji
AU - Oluwatoyosi, Mercy Adaramodu
AU - Orege, Joshua Iseoluwa
AU - Ayeni, Emmanuel Ayodeji
AU - Ibrahim, Yusuf Ajibola
AU - Adeyemi, Sherif Babatunde
AU - Tiamiyu, Bashir Bolaji
AU - Gbadegesin, Lanre Anthony
AU - Akinyemi, Toluwanimi Oluwadara
AU - Odoh, Chuks Kenneth
AU - Umeobi, Happiness Ijeoma
AU - Adeoye, Adenike Bernice Eloise
N1 - Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/1
Y1 - 2021/1
N2 - The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last Ebola epidemic, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in order to find treatments for SARS-CoV-2 infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulants used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-à-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.
AB - The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last Ebola epidemic, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in order to find treatments for SARS-CoV-2 infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulants used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-à-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.
KW - Antiviral drugs
KW - COVID-19
KW - Drug interaction
KW - Health and safety
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85097567166&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2020.107228
DO - 10.1016/j.intimp.2020.107228
M3 - Review article
C2 - 33302035
AN - SCOPUS:85097567166
SN - 1567-5769
VL - 90
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 107228
ER -
